Condition (MeSH)
Breast Neoplasms, Male
ClinicalTrials.gov lists 286 trials for Breast Neoplasms, Male or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 57.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
286 of the 286 trials are tagged with Breast Neoplasms, Male itself; the rest are tagged with a narrower condition beneath it.
When did Breast Neoplasms, Male trials start? (30)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 31
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 6 |
| 2017 | 4 |
| 2016 | 4 |
| 2015 | 2 |
Showing 10 of 30 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Breast Neoplasms, Male trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 73 |
| Phase 1/2 | 29 |
| Phase 2 | 102 |
| Phase 3 | 20 |
| Not applicable | 33 |
| Observational | 29 |
How many Breast Neoplasms, Male trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 6 |
| Active, not recruiting | 5 |
| Completed | 202 |
| Terminated | 43 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Breast Neoplasms, Male trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 57 |
| SWOG Cancer Research Network | 6 |
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| National Institutes of Health Clinical Center (CC) | 4 |
Which drugs are being tested for Breast Neoplasms, Male? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 31 |
| TRASTUZUMAB | 29 |
| (nab)-paclitaxel | 28 |
| LAPATINIB | 15 |
| "Capecitabine" | 14 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Docetetaxel | 22 |
| Doxorubicine | 20 |
| Radiation Therapy | 15 |
| Bevacizumab 1 | 13 |
| Tamoxifen Pill | 12 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Breast Neoplasms, Male trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Fatigue | 224 | 28 |
| Neutropenia | 142 | 12 |
| Diarrhea | 141 | 26 |
| Neutrophil count decreased | 117 | 13 |
| Nausea | 104 | 24 |
Showing 5 of 10 adverse events.
Which publications cover Breast Neoplasms, Male? (107)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer. | The New England journal of medicine | 2026 | Yes |
| Overall Survival with Inavolisib in <i>PIK3CA</i>-Mutated Advanced Breast Cancer. | The New England journal of medicine | 2025 | Yes |
| Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. | The New England journal of medicine | 2025 | Yes |
| Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial. | JAMA oncology | 2025 | Yes |
| Inavolisib-Based Therapy in <i>PIK3CA</i>-Mutated Advanced Breast Cancer. | The New England journal of medicine | 2024 | Yes |
Showing 5 of 107 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.